Concurrent Myeloperoxidase-ANCA Positivity and Type III Mixed Cryoglobulinemia After Tumor Necrosis Factor-α Inhibition (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0781; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "TNF-α inhibitor was discontinued , and the patient was started on prednisone and Rituximab. The patient's favorable response to Rituximab, with resolution of cryoglobulins, declining ANCA titers, and improvement in kidney function, supports B-cell-directed therapy as a potentially effective treatment strategy in TNF-α inhibitor-associated overlap vasculitic syndromes. Clinicians should maintain a high index of suspicion for secondary autoimmune phenomena in patients receiving TNF- α inhibitors who develop otherwise unexplained kidney dysfunction or systemic inflammatory findings."
ANCA Vasculitis • Complement-mediated Rare Disorders • Dyslipidemia • Genito-urinary Cancer • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Nephrology • Oncology • Prostate Cancer • Renal Disease • Rheumatoid Arthritis • Solid Tumor • Vasculitis • MPO
|
|
Ahmed E. Subahi; Kristen Tomaszewski; Loai Dweik; Juliette Yedimenko; Ali Mehdi
|